Products for Research Use Only
RegisterLogin

Imatinib Impurity E

CAT: 0804-HY-131275-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-131275-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].
CAS Number
1365802-18-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Drug Metabolite
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/imatinib-impurity-e.html
Purity
96.05
Solubility
DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C4=CC=C(CN5CCN(CC6=CC=C(C=C6)C(NC7=CC=C(C)C(NC8=NC=CC(C9=CC=CN=C9)=N8)=C7)=O)CC5)C=C4
Molecular Formula
C52H48N12O2
Molecular Weight
873.02
Precautions
H302, H315, H319, H335
References & Citations
[1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.|[4]Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97 (8) :2440-8.|[5]Jeanne M Sisk, et al. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99 (5) :619-630.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-Z4127-01Imatinib impurity 2
HY-Z3643-01Imatinib impurity 12
HY-Z2065-01Imatinib impurity 21
HY-15463-01Imatinib
HY-15463S1-01Imatinib-d4
HY-111849-01Imatinib carbaldehyde
HY-50946-01Imatinib (Mesylate)
HY-15463S-01Imatinib-d8
HY-135638-01Imatinib Acid
HY-15463R-01Imatinib (Standard)

Alternative Products

CatalogName
AR-I01302-01Imatinib Impurity A
RM-I132081-01Imatinib Impurity 81
RM-I132068-01Imatinib Impurity 68
RM-I132069-01Imatinib Impurity 69
RM-I132070-01Imatinib Impurity 70
RM-I132062-01Imatinib Impurity 62
RM-I132058-01Imatinib Impurity 58
RM-I132057-01Imatinib Impurity 57
RM-I132054-01Imatinib Impurity 54
RM-I132049-01Imatinib Impurity 23

Popular Products